Corresponding Author: Elizabeth Garrett-Mayer, PhD, Center for Research and Analytics, American Society of Clinical Oncology, 2318 Mill Rd, Ste 800, Alexandria, VA 22314 (liz.garrett-mayer@asco.org).
Published Online: October 29, 2020. doi:10.1001/jamaoncol.2020.4886
Conflict of Interest Disclosures: Dr Rini reported receiving grants and personal fees from AVEO Pharmaceuticals, Bristol Myers Squibb, Genentech, Merck, and Pfizer and personal fees from Alkermes, Aravive, AstraZeneca, and GlaxoSmithKline outside the submitted work. No other disclosures were reported.
1.Hartman
HE , Sun
Y , Devasia
TP ,
et al. Integrated survival estimates for cancer treatment delay among adults with cancer during the COVID-19 pandemic.
JAMA Oncol. Published online October 29, 2020. doi:
10.1001/jamaoncol.2020.5403Google Scholar 2.Bertuzzi
AF , Marrari
A , Gennaro
N ,
et al. Low incidence of SARS-CoV-2 in patients with solid tumours on active treatment: an observational study at a tertiary cancer centre in Lombardy, Italy.
Cancers (Basel). 2020;12(9):E2352. doi:
10.3390/cancers12092352
PubMedGoogle Scholar 5.Sanchez-Pina
JM , Rodriguez
MR , Quismondo
NC ,
et al. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies.
Eur J Haematol. Published online July 24, 2020. doi:
10.1111/ejh.13493
PubMedGoogle Scholar